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Abstract The conditions for the formation of a non-covalent
complex between 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
and the human transport fetal protein, K-fetoprotein (AFP), have
been studied. TCDD has been shown to form a stable complex
with AFP in a 2:1 (TCDD:AFP) ratio. The apparent solubility
of TCDD in water increases 105-fold after complex formation.
The toxicity of the TCDD:AFP complex injected into mice by
the intravenous route is comparable with that of free TCDD
administered in oil solution per os. The complex manifests very
much higher toxicity (200^1400 times) against human tumor
cells (CEM, MCF-7, HepG2) in vitro and surpasses TCDD in
selectivity. AFP may facilitate TCDD transport in embryonic
tissues and enhance its embryotoxic and teratogenic effects.
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1. Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), commonly
referred to as dioxin, belongs to the class of the most hazard-
ous environmental contaminants. It is formed as a by-product
in many technological processes and manifests high environ-
mental stability and a broad spectrum of biological activities.
Polychlorinated dioxins and many related compounds (poly-
chlorinated dibenzofurans, biphenyls and other aromatic hy-
drocarbons) are distinguished for high toxicity and carcinoge-
nicity [1^5]. Besides, they promote carcinogenesis and are
endowed with immunotoxic, embryotoxic, teratogenic and
neurotoxic activities [6^8]. These compounds can also produce
atrophic changes in lymphoid organs (thymus, spleen, lymph
nodes) and in£uence the function of adrenal, thyroid, mam-
mary and sex glands [6,8]. The characteristic property of
TCDD which sets it apart from the majority of toxic com-
pounds is that the life span of experimental animals in acute
toxicity studies only weakly depends on its dose; animal death
occurs as a result of the so-called wasting syndrome mani-
fested as progressive and irreversible loss of body weight [8].
Other distinctive features of TCDD are signi¢cant interspe-
ci¢c di¡erences in acute toxic e¡ects [9^11] and high embry-
otoxicity [12^14].
The aim of the present work was to study the interaction of
TCDD with the fetal transport protein human K-fetoprotein
(AFP), and to examine the biological properties of the trans-
port form of TCDD after its binding to AFP in experiments
with mice and human tumor cells.
2. Materials and methods
TCDD (Cambridge Isotopes Lab, USA) was dissolved in HPLC-
grade 1,4-dioxane (Fluka, Switzerland) at 0.8^0.9 mg/ml concentra-
tion. The solution was stored in argon atmosphere at 4‡C. Human
AFP was isolated as described previously [15].
TCDD dissolved in 1,4-dioxane was added slowly upon gentle
shaking to a solution of AFP (protein concentration was 1.5^2.0 mg/
ml) in phosphate-bu¡ered saline pH 7.4 (PBS) to a ¢nal 1,4-dioxane
concentration of not more than 5% (v/v). The reaction mixture was
incubated for 1^6 h at 30^37‡C. After incubation the AFP:TCDD
complex was separated from low molecular weight components on a
Sephadex G-25sf column (Pharmacia, Sweden) equilibrated with PBS
containing 10% acetonitrile (v/v) (HPLC-grade, Fluka, Switzerland).
The fractions of the target complex were combined and stored at 4‡C
until analysis (as a rule, for no longer than 48 h). For long-term
storage dry mannitol (up to 10% w/v) was added to AFP:TCDD,
after which the solution was passed through a micro-¢lter (0.22 Wm)
under sterile conditions, poured out into glass tubes, frozen and
lyophilized. After freeze-drying the tubes were ¢lled with argon, sol-
dered up and stored at 370‡C.
TCDD was quantitatively assayed by reverse phase HPLC on a
‘GOLD’ liquid chromatograph (Beckman, USA). The chromato-
graphic system consisted of a gradient pump M-126 (Beckman,
USA), a loop injector M-7125 (loop volume 500 Wl) (Rheodyne,
USA), an 0.46U7.5 cm Ultrasphere Octyl column (3 W) and a £ow
spectrophotometer M-167 (Beckman, USA). The separation was per-
formed at a £ow rate of 1.5 ml/min as linear gradient elution of
component B (65^85%) (A = 0.1 M ammonium acetate, pH 6.0, 10%
acetonitrile (v/v); B = 50:50 acetonitrile:isopropanol) for 10 min. The
TCDD:AFP complex was applied onto the column in a volume of 5^
500 Wl. The assay was performed by the external standard method
using a TCDD solution in 1,4-dioxane (0.1^0.2 mg/ml). Peak area
measurements and treatment of experimental results were performed
using a chromatographic program ‘GOLD Personal Chromatograph’
(Beckman, USA). Mean values were obtained from three parallel
concentration measurements in both sample and standard solutions.
The experimental error was calculated by the least squares method.
Acute toxicity of the TCDD:AFP complex (0.05^2.0 mg/kg) was
estimated in experiments with C57BL/6 mice of both sexes (18^20 g
body weight). Control groups included 10 animals; each experimental
group consisted of six animals. The solution of the TCDD:AFP
complex in PBS was injected into the tail vein in the volume of 0.1^
0.15 ml. The death of experimental animals was followed up to day 45
after the injection. LD50 was calculated by the probit method; mean
values and standard deviation were calculated at P = 0.05.
The biological activity of the TCDD:AFP complex in vitro was
tested in experiments with the following human tumor cell lines:
CEM (T-cell lymphoma), MCF-7 (mammary carcinoma) and
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HepG2 (hepatoma). CEM cells were cultured in RPMI 1640 medium
(Sigma, USA) supplemented with 10% FBS (Gibco, USA), 100 U/ml
penicillin and 100 Wg/ml streptomycin. MCF-7 and HepG2 cells were
cultured under identical conditions except that DMEM medium (Sig-
ma, USA) was used. Cytotoxic activities of TCDD and its complex
with AFP were determined with the MTT test using the method of
Mosmann [16]. TCDD was added to the cell medium in isopropanol;
TCDD:AFP was added in PBS.
3. Results
Measurements of TCDD concentration in the complex pre-
pared at various TCDD:AFP ratios (2^10 molar excess of
TCDD) revealed that the AFP molecule has two binding sites
for TCDD. After separation of the protein from an excess of
non-bound ligand the TCDD concentration within the com-
plex varied from 2 to 12 Wg/ml. After concentration of the
TCDD:AFP complex by ultra¢ltration on a YM-10 mem-
brane (Amicon, The Netherlands) samples with TCDD con-
centration of up to 25^30 Wg/ml were obtained.
The toxicity of the TCDD:AFP complex and sex-related
di¡erences in the sensitivity of experimental animals to its
e¡ect were studied in C57BL/6 mice of both sexes. The exper-
imental values of LD50 and average life spans of experimental
mice are given in Table 1.
The cytotoxicity of the TCDD:AFP complex against all the
cell lines tested in this study appeared to be much higher than
that of free dioxin. Noteworthy, the di¡erence in the sensitiv-
ity of cells of various lines to the e¡ect of free TCDD was
pronounced in a much lesser degree (IC50 = 0.7^8 WM). T-cell
lymphoma (CEM) cells manifested the highest sensitivity to
the e¡ect of the TCDD:AFP complex (IC506 0.50 nM).
Mammary adenocarcinoma cells (MCF-7) were more resistant
(IC50 = 18 nM), while HepG2 hepatoma cells were the least
sensitive under the given experimental conditions (IC50 =
52 nM).
4. Discussion
The data presented in Table 1 suggest that the TCDD:AFP
complex administered as described above manifests higher
toxicity in comparison with per os administration of free di-
oxin as a micellar suspension in a non-ionic detergent (1.18
and 1.62 mg/kg for female and male albino mice, respectively)
but was less toxic in comparison with dioxin administered per
os in vegetable oil (LD50 for albino mice was 0.046 mg/kg) [9].
The literature values of LD50 for male C57BL/6 mice to which
TCDD was administered orally in vegetable oil are 114 [17]
and 283 Wg/kg [10]. The corresponding values for male
C57BL/6 mice obtained in this study indicated that acute tox-
icity of TCDD injected intravenously as a AFP:TCDD com-
plex di¡ers signi¢cantly from the toxicity of free TCDD ad-
ministered per os in oil solution. The observed di¡erences in
the LD50 values for male and female mice are signi¢cant at
P = 0.05 which testi¢es to sex-related distinctions in the sensi-
tivity of mice of this particular strain to the e¡ect of the
compound tested. The results of this study corroborate the
literature data according to which female mice are more sen-
sitive to the toxic e¡ect of TCDD administered by alternative
routes [9].
A graphic representation of the IC50 values of the
TCDD:AFP complex for human tumor cell cultures is given
in Fig. 1. Relative toxicities of dioxin and its complex with
AFP for the same cell lines are displayed in Fig. 2. As seen,
the di¡erence in the sensitivity of human tumor cells to
TCDD:AFP between the most and least sensitive lines is
much higher than in the case of relative cytotoxicity (see
Fig. 2).
Stipulating extremely low solubility of TCDD in water
(V20 ng/l) [18], it may be concluded that the apparent sol-
ubility of dioxin increases more than 105-fold during the for-
mation of the TCDD:AFP complex. By forming a complex
with TCDD, AFP converts this compound into a ‘transport’
form and thus facilitates its delivery to various embryonic
Fig. 1. Toxicity of the TCDD:AFP complex against human tumor
cells in vitro.
Fig. 2. Relative toxicity of the TCDD:AFP complex versus toxicity
of free TCDD against human tumor cells.
Table 1
Toxicity for mice of the non-covalent TCDD:AFP complex administered by the intravenous route
Strain Sex LD50 (mg/kg) Average life span (days) Life span (days, min^max)
C57BL/6 Female 0.33 þ 0.08 17.0 þ 2.6 13^20
Male 1.10 þ 0.17 13.9 þ 2.8 11^17
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organs and tissues. Cytotoxicity data also provide evidence
that the formation of the TCDD:AFP complex not only in-
creases the solubility of this environmental toxicant in aque-
ous media but strongly enhances the selectivity of its biolog-
ical e¡ect on tumor cells from various human tissues. A
comparison of cytotoxic e¡ects of free dioxin and the
TCDD:AFP complex for the most and least sensitive cell lines
(CEM and HepG2, respectively) revealed that the IC50 values
of dioxin for these cells di¡er between themselves by about
one order of magnitude, while for the TCDD:AFP complex
this di¡erence is two orders of magnitude (8/0.7 = 11 and 52/
0.5 = 104).
In this study we have developed a model of selective deliv-
ery of TCDD to target cells using AFP as a vector molecule.
It is generally believed that in an embryonic organism AFP
mainly ful¢lls the transport function by providing e⁄cient
exchange of free fatty acids, hormones and some other metab-
olites [19]. It has been found that apart from its high a⁄nity
for fatty acids, AFP has several binding sites (2^8) for steroid
hormones, bilirubin and a great variety of medicinal drugs
[20].
Taking into account the high e⁄ciency of the transport
function of AFP in vivo as well as the high hydrophobicity
and some structural features of the TCDD molecule, it
seemed appropriate to use AFP for targeted delivery of
TCDD to human tumor cells in model systems and to eluci-
date the reasons for its high embryotoxicity.
This approach has made it possible to obtain a stable non-
covalent complex in a ligand:protein molar ratio of 2:1. The
formation of the TCDD:AFP complex caused a more than
105-fold increase in the apparent solubility of TCDD. It may
thus be assumed that it is the formation of the TCDD com-
plex with the major fetal transport protein, AFP, which mark-
edly increases the e⁄ciency of its targeted delivery to various
embryonic organs and is responsible for its high embryotox-
icity and teratogenicity.
The results of cytotoxicity studies of the TCDD:AFP com-
plex in vitro as well as some evidence for high antiestrogenic
activity of TCDD [21^24] point to the expediency of investi-
gation of antitumor activity of the newly synthesized
TCDD:AFP complex against hormone-dependent tumors in
vivo.
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